(R)-Pemetrexed (BioDeep_00000841764)
代谢物信息卡片
(R)-Pemetrexed
化学式: C20H21N5O6 (427.14917660000003)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O
InChI: InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m1/s1
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jingya Zhou, Shouhong Gao, Feng Zhang, Bo Jiang, Qin Zhan, Fei Cai, Jingxian Li, Wansheng Chen. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Oct; 906(?):1-8. doi:
10.1016/j.jchromb.2012.07.033. [PMID: 22959676] - I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, A R A Razak, A D Colevas, F A Shepherd, N B Leighl, J W Neal, A Thibault, L Liu, J Lisano, B Gao, E B Lawson, H A Wakelee. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
British journal of cancer.
2012 Aug; 107(4):604-11. doi:
10.1038/bjc.2012.319. [PMID: 22805331] - Yasuhiko Sakata, Yasuo Iwamoto, Junya Inata, Shunji Matsumoto, Shinichi Miyamori, Kazutoshi Nakashima, Shinjiro Sakamoto, Masashi Kanehara, Souichi Kitaguchi, Kouichi Hiraki. [Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy].
Gan to kagaku ryoho. Cancer & chemotherapy.
2012 Jun; 39(6):927-32. doi:
NULL. [PMID: 22705687] - Josefine Reber, Harriet Struthers, Thomas Betzel, Alexander Hohn, Roger Schibli, Cristina Müller. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Molecular pharmaceutics.
2012 May; 9(5):1213-21. doi:
10.1021/mp200511t. [PMID: 22509996] - Setsuko K Chambers, H-H Sherry Chow, Mike F Janicek, Janiel M Cragun, Kenneth D Hatch, Haiyan Cui, Cynthia Laughren, Mary C Clouser, Janice L Cohen, Heather M Wright, Nisreen Abu Shahin, David S Alberts. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012 May; 18(9):2668-78. doi:
10.1158/1078-0432.ccr-12-0261. [PMID: 22421191] - Xiaolan Feng, Liena Zhao, Guangming Han, Moosa Khalil, Francis Green, Travis Ogilvie, Vanessa Krause. A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.
Rare tumors.
2012 Apr; 4(2):e21. doi:
10.4081/rt.2012.e21. [PMID: 22826778] - Natallia Maroz, I David Weiner. Secondary capillary leak syndrome related to pemetrexed exposure.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2012 Apr; 59(4):582-3; author reply 583. doi:
10.1053/j.ajkd.2011.12.031. [PMID: 22444494] - Constantin A Dasanu, Aileen Ong-Bacay, Ion Codreanu. Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2012 Mar; 18(1):97-103. doi:
10.1177/1078155210394695. [PMID: 21248173] - Oluf Dimitri Røe, Adam Szulkin, Endre Anderssen, Arnar Flatberg, Helmut Sandeck, Tore Amundsen, Sten Even Erlandsen, Katalin Dobra, Stein Harald Sundstrøm. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
PloS one.
2012; 7(8):e40521. doi:
10.1371/journal.pone.0040521. [PMID: 22905093] - Lana Bijelic, O Anthony Stuart, Paul Sugarbaker. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma.
Gastroenterology research and practice.
2012; 2012(?):890450. doi:
10.1155/2012/890450. [PMID: 22927839] - Suzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, Marianne Nicolson, Jan H M Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2011 Dec; 68(6):1619-28. doi:
10.1007/s00280-011-1732-7. [PMID: 21953275] - Hiroyuki Suzuki, Jun Ohsugi, Takaharu Saito, Mika Hoshino, Mitsunori Higuchi, Masatoshi Kitamura, Akihiro Kudoh, Sanae Midorikawa, Mitsukazu Gotoh. [Renal-salt wasting syndrome in a patient with CDDP containing chemotherapy for recurrent non-small-cell lung cancer].
Gan to kagaku ryoho. Cancer & chemotherapy.
2011 Dec; 38(13):2635-8. doi:
NULL. [PMID: 22189232] - Ning Wu, Qiang Li, Chang-Xin Gu, Toqeer Ahmed, Xiao-Peng Yao. Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: a case report.
BMC cancer.
2011 Nov; 11(?):487. doi:
10.1186/1471-2407-11-487. [PMID: 22085873] - Kevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, Eliane Kellen, Catherine Legrand, Yoshiro Kishi, Joris R Delanghe, Jan P van Meerbeeck. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2011 Nov; 6(11):1930-7. doi:
10.1097/jto.0b013e3182272294. [PMID: 21841505] - Ilya G Glezerman, M Catherine Pietanza, Vincent Miller, Surya V Seshan. Kidney tubular toxicity of maintenance pemetrexed therapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2011 Nov; 58(5):817-20. doi:
10.1053/j.ajkd.2011.04.030. [PMID: 21849225] - Yi Jiang, Ling-shuang Liu, Chun-jie Li. [Effect of Chinese medicine comprehensive regimen as the maintenance therapy on time to progression and quality of life of patients with advanced non-small-cell lung cancer].
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.
2011 Oct; 31(10):1311-6. doi:
". [PMID: 22097195] - Cristina Müller, Iontcho R Vlahov, Hari Krishna R Santhapuram, Christopher P Leamon, Roger Schibli. Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.
Nuclear medicine and biology.
2011 Jul; 38(5):715-23. doi:
10.1016/j.nucmedbio.2010.12.013. [PMID: 21718947] - Jens Benn Sørensen. Pharmacokinetic evaluation of pemetrexed.
Expert opinion on drug metabolism & toxicology.
2011 Jul; 7(7):919-28. doi:
10.1517/17425255.2011.587411. [PMID: 21599552] - Nikolas Harbord. Novel nephrotoxins.
Advances in chronic kidney disease.
2011 May; 18(3):214-8. doi:
10.1053/j.ackd.2010.12.001. [PMID: 21531328] - Isam Abdel-Karim, William K Plunkett, Susan O'Brien, Francis Giles, Deborah Thomas, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Min Du, Karen B Schneck, Victor J Chen, Boris K Lin, Steven J Nicol, Hagop M Kantarjian. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
Investigational new drugs.
2011 Apr; 29(2):323-31. doi:
10.1007/s10637-009-9369-7. [PMID: 20091088] - Anthony W Tolcher, Leonard J Appleman, Geoffrey I Shapiro, Alain C Mita, Frank Cihon, Arthur Mazzu, Pavur R Sundaresan. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Cancer chemotherapy and pharmacology.
2011 Apr; 67(4):751-64. doi:
10.1007/s00280-010-1372-3. [PMID: 20521052] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Kappusamy Saravanan, Hannah C Barlow, Marion Barton, A Hilary Calvert, Bernard T Golding, David R Newell, Julian S Northen, Nicola J Curtin, Huw D Thomas, Roger J Griffin. Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
Journal of medicinal chemistry.
2011 Mar; 54(6):1847-59. doi:
10.1021/jm101493z. [PMID: 21366300] - Charles M Rudin, Ann Mauer, Martin Smakal, Rosalyn Juergens, Stanislav Spelda, Michael Wertheim, Andrew Coates, Evelyn McKeegan, Peter Ansell, Xiangdong Zhou, Jane Qian, Rajendra Pradhan, Barry Dowell, Andrew Krivoshik, Gary Gordon. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011 Mar; 29(8):1075-82. doi:
10.1200/jco.2010.32.5944. [PMID: 21300929] - Reason Wilken, Mysore S Veena, Marilene B Wang, Eri S Srivatsan. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.
Molecular cancer.
2011 Feb; 10(?):12. doi:
10.1186/1476-4598-10-12. [PMID: 21299897] - Xiaojiang Sun, Liming Sheng, Qinghua Deng, Peng Liu, Ke Lu. Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.
Pharmacology.
2011; 88(5-6):242-4. doi:
10.1159/000331866. [PMID: 21997597] - Scott B Rothbart, Alexandra C Racanelli, Richard G Moran. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
Cancer research.
2010 Dec; 70(24):10299-309. doi:
10.1158/0008-5472.can-10-1873. [PMID: 21159649] - N Janus, V Launay-Vacher, E Byloos, J-P Machiels, L Duck, J Kerger, W Wynendaele, J-L Canon, W Lybaert, J Nortier, G Deray, H Wildiers. Cancer and renal insufficiency results of the BIRMA study.
British journal of cancer.
2010 Dec; 103(12):1815-21. doi:
10.1038/sj.bjc.6605979. [PMID: 21063408] - Roland J W Meesters, Robin Cornelissen, Rob J van Klaveren, Robert de Jonge, Ethan den Boer, Jan Lindemans, Theo M Luider. A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients.
Analytical and bioanalytical chemistry.
2010 Dec; 398(7-8):2943-8. doi:
10.1007/s00216-010-4192-8. [PMID: 20865407] - Tobias L Ross, Michael Honer, Cristina Müller, Viola Groehn, Roger Schibli, Simon M Ametamey. A new 18F-labeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2010 Nov; 51(11):1756-62. doi:
10.2967/jnumed.110.079756. [PMID: 20956469] - Jennifer A Chan, Andrew X Zhu, Keith Stuart, Pankaj Bhargava, Craig C Earle, Jeffrey W Clark, Carolyn Casey, Eileen Regan, Matthew H Kulke. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.
Cancer chemotherapy and pharmacology.
2010 Oct; 66(5):961-8. doi:
10.1007/s00280-010-1248-6. [PMID: 20130879] - Sara Nannizzi, Gareth J Veal, Elisa Giovannetti, Valentina Mey, Simona Ricciardi, Christopher J Ottley, Mario Del Tacca, Romano Danesi. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
Cancer chemotherapy and pharmacology.
2010 Aug; 66(3):547-58. doi:
10.1007/s00280-009-1195-2. [PMID: 20020129] - Yohannes Hagos, Natascha A Wolff. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.
Toxins.
2010 08; 2(8):2055-82. doi:
10.3390/toxins2082055. [PMID: 22069672] - Chiharu Tanai, Nobuyuki Yamamoto, Yuichiro Ohe, Toshiaki Takahashi, Hideo Kunitoh, Haruyasu Murakami, Noboru Yamamoto, Yukiko Nakamura, Hiroshi Nokihara, Takehito Shukuya, John R Baldwin, Minori Koshiji, Tomohide Tamura. A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2010 Jul; 5(7):1068-74. doi:
10.1097/jto.0b013e3181da3899. [PMID: 20453691] - Jan Gerard Maring, Floris M Wachters, Monique Slijfer, J Marina Maurer, H Marike Boezen, Donald R A Uges, Elisabeth G E de Vries, Harry J M Groen. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
European journal of clinical pharmacology.
2010 Jun; 66(6):611-7. doi:
10.1007/s00228-010-0799-0. [PMID: 20213492] - Nicolas J Dickgreber, Jens Benn Sorensen, Luis G Paz-Ares, Tine Kjestrup Schytte, Jane E Latz, Karen B Schneck, Zheng Yuan, José Miguel Sanchez-Torres. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 May; 16(10):2872-80. doi:
10.1158/1078-0432.ccr-09-3324. [PMID: 20460481] - Robin E Norris, Peter C Adamson. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Cancer chemotherapy and pharmacology.
2010 May; 65(6):1125-30. doi:
10.1007/s00280-009-1120-8. [PMID: 19784838] - Cristina Müller, Joseph A Reddy, Christopher P Leamon, Roger Schibli. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
Molecular pharmaceutics.
2010 Apr; 7(2):597-604. doi:
10.1021/mp900296k. [PMID: 20199053] - Jia Li, Man Yee Merl, Muhammad Wasif Saif. Any second-line therapy for advanced pancreatic cancer? Highlights from the '2010 ASCO Gastrointestinal Cancers Symposium'. Orlando, FL, USA. January 22-24, 2010.
JOP : Journal of the pancreas.
2010 Mar; 11(2):151-3. doi:
". [PMID: 20208325] - Daniel Gilbert Weber, Georg Johnen, Dirk Taeger, Anne Weber, Isabelle Mercedes Gross, Beate Pesch, Thomas Kraus, Thomas Brüning, Monika Gube. Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.
Biomarker insights.
2010 Jan; 5(?):1-8. doi:
10.4137/bmi.s3927. [PMID: 20130785] - Yu Ri Seo, Se Hyung Kim, Hyun Jung Kim, Chan Kyu Kim, Seong Kyu Park, Eun Suk Koh, Dae Sik Hong. Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
Journal of hematology & oncology.
2010 Jan; 3(?):4. doi:
10.1186/1756-8722-3-4. [PMID: 20089186] - G Mickisch, M Gore, B Escudier, G Procopio, S Walzer, M Nuijten. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
British journal of cancer.
2010 Jan; 102(1):80-6. doi:
10.1038/sj.bjc.6605417. [PMID: 19920817] - S C H Kao, V H Phan, S J Clarke. Predictive markers for haematological toxicity of pemetrexed.
Current drug targets.
2010 Jan; 11(1):48-57. doi:
10.2174/138945010790031072. [PMID: 19839928] - Robert Pirker, Wilma Minar. Chemotherapy of advanced non-small cell lung cancer.
Frontiers of radiation therapy and oncology.
2010; 42(?):157-163. doi:
10.1159/000262471. [PMID: 19955802] - Aristeidis Stavroulopoulos, Lydia Nakopoulou, Antonios M Xydakis, Vasiliki Aresti, Aggeliki Nikolakopoulou, Georgios Klouvas. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.
Renal failure.
2010; 32(8):1000-4. doi:
10.3109/0886022x.2010.501930. [PMID: 20722569] - Minglun Li, Amir Abdollahi, Hermann-Josef Gröne, Kenneth E Lipson, Claus Belka, Peter E Huber. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model.
Radiation oncology (London, England).
2009 Dec; 4(?):66. doi:
10.1186/1748-717x-4-66. [PMID: 20025728] - Mark A Socinski, Egbert F Smit, Paul Lorigan, Kartik Konduri, Martin Reck, Aleksandra Szczesna, Johnetta Blakely, Piotr Serwatowski, Nina A Karaseva, Tudor Ciuleanu, Jacek Jassem, Mircea Dediu, Shengyan Hong, Carla Visseren-Grul, Axel-Rainer Hanauske, Coleman K Obasaju, Susan C Guba, Nick Thatcher. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Oct; 27(28):4787-92. doi:
10.1200/jco.2009.23.1548. [PMID: 19720897] - A-R Hanauske, M Lahn, L C Musib, K Weigang-Köhler, E Yilmaz, T Graefe, B Kuenen, D Thornton, P McNealy, G Giaccone. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2009 Sep; 20(9):1565-1575. doi:
10.1093/annonc/mdp049. [PMID: 19487488] - C Bobin-Dubigeon, M B Amiand, C Herrenknecht, J M Bard. Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Aug; 877(24):2451-6. doi:
10.1016/j.jchromb.2009.06.020. [PMID: 19560408] - Huw D Thomas, Kappusamy Saravanan, Lan-Zhen Wang, Mei-Ju Lin, Julian S Northen, Hannah Barlow, Marion Barton, David R Newell, Roger J Griffin, Bernard T Golding, Nicola J Curtin. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.
Molecular cancer therapeutics.
2009 Jul; 8(7):1828-37. doi:
10.1158/1535-7163.mct-08-1208. [PMID: 19509274] - Justine Bacchetta, Dominique Ranchère, Frédérique Dijoud, Jean-Pierre Droz. Mesothelioma of the testis and nephrotic syndrome: a case report.
Journal of medical case reports.
2009 Jun; 3(?):7248. doi:
10.1186/1752-1947-3-7248. [PMID: 19830148] - Joaquim Bosch-Barrera, Alberto Montero, José María López-Picazo, Jesús García-Foncillas, Marta Ferrer, José Ramón Yuste, Ignacio Gil-Bazo. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands).
2009 Apr; 64(1):124-6. doi:
10.1016/j.lungcan.2008.09.013. [PMID: 19008012] - Laurent Greillier, Suzanne Monjanel-Mouterde, Anne Fraticelli, Bénédicte Devictor-Pierre, Julien Bouvenot, Nicolas Coltel, Gérald Lamarche, Philippe Astoul. Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2009 Mar; 4(3):404-8. doi:
10.1097/jto.0b013e318197f302. [PMID: 19247087] - Per Byström, Karin Björkegren, Anders Larsson, Linda Johansson, Ake Berglund. Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer.
Upsala journal of medical sciences.
2009; 114(3):160-4. doi:
10.1080/03009730903027172. [PMID: 19736606] - J M Peña Porta, C Vicente de Vera Floristán, P Bueso Inglán, J Florián Jericó. [Acute renal failure associated with Pemetrexed (Alimta)].
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
2009; 29(6):610-1. doi:
10.3265/nefrologia.2009.29.6.5492.en.full. [PMID: 19936010] - Robert Mauritz, Godefridus J Peters, Ietje Kathmann, Habte Teshale, Paul Noordhuis, Elizabeth M Comijn, Herbert M Pinedo, Gerrit Jansen. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Cancer chemotherapy and pharmacology.
2008 Nov; 62(6):937-48. doi:
10.1007/s00280-008-0683-0. [PMID: 18283461] - Cristina Müller, Roger Schibli, Eric P Krenning, Marion de Jong. Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2008 Apr; 49(4):623-9. doi:
10.2967/jnumed.107.047704. [PMID: 18344429] - K S Han, J Y Joung, T S Kim, I G Jeong, H K Seo, J Chung, K H Lee. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.
British journal of cancer.
2008 Jan; 98(1):86-90. doi:
10.1038/sj.bjc.6604113. [PMID: 18087289] - K M Li, L P Rivory, S J Clarke. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
British journal of cancer.
2007 Oct; 97(8):1071-6. doi:
10.1038/sj.bjc.6603995. [PMID: 17912246] - Amy E Smith, Michael Pinkney, Nigel H Piggott, Hilary Calvert, Ian D Milton, John Lunec. A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.
Hybridoma (2005).
2007 Oct; 26(5):281-8. doi:
10.1089/hyb.2007.0512. [PMID: 17979543] - M Candelaria, D Gallardo-Rincón, C Arce, L Cetina, J L Aguilar-Ponce, O Arrieta, A González-Fierro, A Chávez-Blanco, E de la Cruz-Hernández, M F Camargo, C Trejo-Becerril, E Pérez-Cárdenas, C Pérez-Plasencia, L Taja-Chayeb, T Wegman-Ostrosky, A Revilla-Vazquez, A Dueñas-González. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2007 Sep; 18(9):1529-38. doi:
10.1093/annonc/mdm204. [PMID: 17761710] - Cristina Müller, P August Schubiger, Roger Schibli. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Nuclear medicine and biology.
2007 Aug; 34(6):595-601. doi:
10.1016/j.nucmedbio.2007.05.011. [PMID: 17707798] - Shrikanta Chattopadhyay, Roni Tamari, Sang H Min, Rongbao Zhao, Eugenia Tsai, I David Goldman. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
The oncologist.
2007 Jul; 12(7):808-15. doi:
10.1634/theoncologist.12-7-808. [PMID: 17673612] - Chris H Takimoto, Lisa A Hammond-Thelin, Jane E Latz, Leonardo Forero, Muralidhar Beeram, Bahram Forouzesh, Johann de Bono, Anthony W Tolcher, Amita Patnaik, Pamela Monroe, Leslie Wood, Karen B Schneck, Romnee Clark, Eric K Rowinsky. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 May; 13(9):2675-83. doi:
10.1158/1078-0432.ccr-06-2393. [PMID: 17473199] - Suman Malempati, H Stacy Nicholson, Joel M Reid, Susan M Blaney, Ashish M Ingle, Mark Krailo, Linda C Stork, Allen S Melemed, Renee McGovern, Stephanie Safgren, Matthew M Ames, Peter C Adamson. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007 Apr; 25(12):1505-11. doi:
10.1200/jco.2006.09.1694. [PMID: 17442992] - J M Ramirez, E M Ocio, J F San Miguel, A Pandiella. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis.
Leukemia.
2007 Apr; 21(4):797-804. doi:
10.1038/sj.leu.2404599. [PMID: 17315026] - Andreas Schneeweiss, Ilka Lauschner, Amparo Ruiz, Angel Guerrero, Pedro Sánchez-Rovira, Miguel Angel Seguí, Kay Goerke, Michael Wolf, Alexeyg G Manikhas, Juergen Wacker, Frederik Marmé, Peter Lichter, Hans-Peter Sinn, Christof Sohn, Kambiz Mansouri, Thomas Bauknecht, Meinhard Hahn. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Clinical breast cancer.
2007 Apr; 7(7):555-8. doi:
10.3816/cbc.2007.n.011. [PMID: 17509164] - Marcel Simon, Johannes Blatter, Christof Granzow. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
Anticancer research.
2007 Mar; 27(2):769-73. doi:
. [PMID: 17465201] - Stacie L Stapleton, Joel M Reid, Patrick A Thompson, Matthew M Ames, Renee M McGovern, Leticia McGuffey, Jed Nuchtern, Robert Dauser, Susan M Blaney. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Cancer chemotherapy and pharmacology.
2007 Mar; 59(4):461-6. doi:
10.1007/s00280-006-0285-7. [PMID: 16855840] - Aude Fléchon. [Gemcitabine and pemetrexed in genito-urinary tumors treatment].
Bulletin du cancer.
2007; 94 Spec No Actualites(?):S116-21. doi:
NULL. [PMID: 17845980] - Cristina Müller, Matthias Brühlmeier, P August Schubiger, Roger Schibli. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2006 Dec; 47(12):2057-64. doi:
. [PMID: 17138750] - Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, Margit Gneist, Filip Janku, Tamara Kysela, Allen Melemed, Jane Latz, Lorinda Simms, Kurt Krejcy. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Dec; 12(23):7071-8. doi:
10.1158/1078-0432.ccr-05-2829. [PMID: 17145830] - Chris H Takimoto, Alain C Mita. Design, conduct, and interpretation of organ impairment studies in oncology patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Jul; 24(21):3509-10; author reply 3510. doi:
10.1200/jco.2006.06.6795. [PMID: 16849773] - A López-Pousa, R Losa, J Martín, J Maurel, J Fra, M Sierra, A Casado, J García Del Muro, A Poveda, C Balañá, J Martínez-Trufero, E Esteban, J M Buesa. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
British journal of cancer.
2006 Jun; 94(12):1797-802. doi:
10.1038/sj.bjc.6603187. [PMID: 16721358] - Kees Hendricksen, Paula M J Moonen, Antoine G van der Heijden, Janneke Molkenboer-Kuenen, Christina A Hulsbergen-van de Kaa, J Alfred Witjes. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Apr; 12(8):2597-601. doi:
10.1158/1078-0432.ccr-05-2644. [PMID: 16638871] - R Sharma, L Rivory, P Beale, S Ong, L Horvath, S J Clarke. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
British journal of cancer.
2006 Apr; 94(7):964-8. doi:
10.1038/sj.bjc.6603049. [PMID: 16552436] - Jane E Latz, Mats O Karlsson, James J Rusthoven, Atalanta Ghosh, Robert D Johnson. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Cancer chemotherapy and pharmacology.
2006 Apr; 57(4):412-26. doi:
10.1007/s00280-005-0077-5. [PMID: 16322990] - Johann C Brandes, Stuart A Grossman, Homaa Ahmad. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
Cancer investigation.
2006 Apr; 24(3):283-7. doi:
10.1080/07357900600629567. [PMID: 16809156] - Giovanni L Ceresoli, Paolo A Zucali, Adolfo G Favaretto, Francesco Grossi, Paolo Bidoli, Guido Del Conte, Anna Ceribelli, Alessandra Bearz, Emanuela Morenghi, Raffaele Cavina, Maurizio Marangolo, Hector J Soto Parra, Armando Santoro. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Mar; 24(9):1443-8. doi:
10.1200/jco.2005.04.3190. [PMID: 16549838] - Miguel Martin. Clinical Experience With Pemetrexed in Breast Cancer.
Seminars in oncology.
2006 02; 33(Suppl 2):S15-8. doi:
10.1053/j.seminoncol.2005.07.027. [PMID: 16472713] - Alain C Mita, Christopher J Sweeney, Sharyn D Baker, Andrew Goetz, Lisa A Hammond, Amita Patnaik, Anthony W Tolcher, Miguel Villalona-Calero, Alan Sandler, Tuhin Chaudhuri, Kathleen Molpus, Jane E Latz, Lorinda Simms, Ajai K Chaudhary, Robert D Johnson, Eric K Rowinsky, Chris H Takimoto. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Feb; 24(4):552-62. doi:
10.1200/jco.2004.00.9720. [PMID: 16391300] - Atiqur Rahman, Robert M White. Cytotoxic anticancer agents and renal impairment study: the challenge remains.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Feb; 24(4):533-6. doi:
10.1200/jco.2005.03.8299. [PMID: 16391294] - Christopher J Sweeney, Chris H Takimoto, Jane E Latz, Sharyn D Baker, Daryl J Murry, James H Krull, Karen Fife, Linda Battiato, Ann Cleverly, Ajai K Chaudhary, Tuhin Chaudhuri, Alan Sandler, Alain C Mita, Eric K Rowinsky. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Jan; 12(2):536-42. doi:
10.1158/1078-0432.ccr-05-1834. [PMID: 16428497] - Vidya Vootukuru, Yin Ping Liew, Joseph V Nally. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.
Medical oncology (Northwood, London, England).
2006; 23(3):419-22. doi:
10.1385/mo:23:3:419. [PMID: 17018900] - Ralph G Zinner, Frank V Fossella, Gregory W Gladish, Bonnie S Glisson, George R Blumenschein, Vassiliki A Papadimitrakopoulou, Katherine M W Pisters, Edward S Kim, Yun W Oh, Beverly O Peeples, Zhishen Ye, Rafael E Curiel, Coleman K Obasaju, Waun K Hong, Roy S Herbst. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Cancer.
2005 Dec; 104(11):2449-56. doi:
10.1002/cncr.21480. [PMID: 16258975] - Haiqing Dai, Ying Chen, William F Elmquist. Distribution of the novel antifolate pemetrexed to the brain.
The Journal of pharmacology and experimental therapeutics.
2005 Oct; 315(1):222-9. doi:
10.1124/jpet.105.090043. [PMID: 15987831] - Grace K Dy, Ajit Suri, Joel M Reid, Jeff A Sloan, Henry C Pitot, Steven R Alberts, Richard M Goldberg, Pamela J Atherton, Lorelei J Hanson, Patrick A Burch, Joseph Rubin, Charles Erlichman, Alex A Adjei. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2005 Jun; 55(6):522-30. doi:
10.1007/s00280-004-0950-7. [PMID: 15754203] - Daniel H Sterman, Steven M Albelda. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Respirology (Carlton, Vic.).
2005 Jun; 10(3):266-83. doi:
10.1111/j.1440-1843.2005.00714.x. [PMID: 15955137] - Vijaya L Damaraju, Katherine F Hamilton, Michelle L Seth-Smith, Carol E Cass, Michael B Sawyer. Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney.
Molecular pharmacology.
2005 Feb; 67(2):453-9. doi:
10.1124/mol.104.004978. [PMID: 15509714] - Rongbao Zhao, Shubing Zhang, Marie Hanscom, Shrikanta Chattopadhyay, I David Goldman. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Feb; 11(3):1294-301. doi:
. [PMID: 15709201] - J S Waters, C Moss, L Pyle, M James, S Hackett, R A'hern, M Gore, T Eisen. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
British journal of cancer.
2004 Nov; 91(10):1763-8. doi:
10.1038/sj.bjc.6602209. [PMID: 15505625] - Alan Hilary Calvert. Biochemical pharmacology of pemetrexed.
Oncology (Williston Park, N.Y.).
2004 Nov; 18(13 Suppl 8):13-7. doi:
. [PMID: 15655931] - Marc Bischof, Peter Huber, Clemens Stoffregen, Michael Wannenmacher, Klaus-Josef Weber. Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases.
International journal of radiation oncology, biology, physics.
2003 Sep; 57(1):289-92. doi:
10.1016/s0360-3016(03)00595-9. [PMID: 12909245] - R Thödtmann, T Sauter, S Weinknecht, L Weissbach, J Blatter, U Ohnmacht, A- R Hanauske. A phase II trial of pemetrexed in patients with metastatic renal cancer.
Investigational new drugs.
2003 Aug; 21(3):353-8. doi:
10.1023/a:1025480914273. [PMID: 14578684] - M Bayés, X Rabasseda, J R Prous. Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology.
2003 Jul; 25(6):483-506. doi:
. [PMID: 12949633] - Cora N Sternberg, Nicholas J Vogelzang. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
Critical reviews in oncology/hematology.
2003 Jun; 46 Suppl(?):S105-15. doi:
10.1016/s1040-8428(03)00068-4. [PMID: 12850531] - Clet Niyikiza, Axel-R Hanauske, James J Rusthoven, A Hilary Calvert, Robert Allen, Paolo Paoletti, Paul A Bunn. Pemetrexed safety and dosing strategy.
Seminars in oncology.
2002 Dec; 29(6 Suppl 18):24-9. doi:
10.1053/sonc.2002.37465. [PMID: 12571807] - Andy Hughes, Paula Calvert, Ashraf Azzabi, Ruth Plummer, Rob Johnson, Jim Rusthoven, Melanie Griffin, Kevin Fishwick, Alan V Boddy, Mark Verrill, Hilary Calvert. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2002 Aug; 20(16):3533-44. doi:
10.1200/jco.2002.10.073. [PMID: 12177114] - Clet Niyikiza, Sharyn D Baker, David E Seitz, Jackie M Walling, Katrina Nelson, James J Rusthoven, Sally P Stabler, Paolo Paoletti, A Hilary Calvert, Robert H Allen. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Molecular cancer therapeutics.
2002 May; 1(7):545-52. doi:
NULL. [PMID: 12479273]